PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies

Research output: Contribution to journalEditorialpeer-review

Abstract

The use of [18F]- and [68Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.

Original languageEnglish (US)
Pages (from-to)485-487
Number of pages3
JournalEuropean Urology
Volume73
Issue number4
DOIs
StatePublished - Apr 2018

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies'. Together they form a unique fingerprint.

Cite this